Taming cardiovascular risk: the promise of LDL cholesterol lowering therapeutics
European Pharmaceutical Review
FEBRUARY 1, 2024
Dr Michael Davidson is CEO of biotech company NewAmsterdam Pharma. We are hopeful that NewAmsterdam Pharma is part of that solution with obicetrapib.” NewAmsterdam Pharma is moving forward into our Phase III trials in the high LDL populations and ultimately, we want to show the benefit of obicetrapib on reducing cardiovascular events.
Let's personalize your content